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Context: Prenatal exposure to maternal cigarette smok-
ing (PEMCS) may affect brain development and behav-
ior in adolescent offspring.
Objective: To evaluate the involvement of the orbito-
frontal cortex (OFC) in mediating the relationship be-
tween PEMCS and substance use.
Design: Cross-sectional analyses from the Saguenay
Youth Study aimed at evaluating the effects of PEMCS
on brain development and behavior among adolescents.
Nonexposed adolescents were matched with adoles-
cents exposed prenatally to cigarette smoking by mater-
nal educational level.
Participants and Setting: A French Canadian
founder population of the Saguenay–Lac-Saint-Jean
region of Quebec, Canada. The behavioral data set in-
cluded 597 adolescents (275 sibships; 12-18 years of age),
half of whom were exposed in utero to maternal ciga-
rette smoking. Analysis of cortical thickness and geno-
typing were performed using available data from 314
adolescents.
Main Outcome Measures: The likelihood of sub-
stance use was assessed with the Diagnostic Interview
Schedule for Children Predictive Scales. The number of
different drugs tried by each adolescent was assessed using
another questionnaire. Thickness of the OFC was esti-
mated from T1-weighted magnetic resonance images using
FreeSurfer software.
Results: Prenatal exposure to maternal cigarette smok-
ing is associated with an increased likelihood of substance
use. Among exposed adolescents, the likelihood of drug
experimentation correlates with the degree of OFC thin-
ning. In nonexposed adolescents, the thickness of the OFC
increases as a function of the number of drugs tried. The
latter effect is moderated by a brain-derived neurotrophic
factor (BDNF) genotype (Val66Met).
Conclusions: We speculate that PEMCS interferes with
the development of the OFC and, in turn, increases the
likelihood of drug use among adolescents. In contrast,
we suggest that, among nonexposed adolescents, drug
experimentation influences the OFC thickness via pro-
cesses akin to experience-induced plasticity.
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C IGARETTE SMOKING DUR-ing pregnancy is not un-common; 16% to 60% ofpregnant women smoke,with the prevalence vary-
ing across countries and socioeconomic
groups. Smoking during pregnancy is as-
sociated with several adverse outcomes
among offspring. The most severe appear
during early development and at birth, in-
cluding spontaneous abortion, smaller
birth weight, and sudden infant death syn-
drome.1 Growing evidence also indicates
increased rates of behavioral problems
among offspring exposed in utero to ma-
ternal cigarette smoking.2,3
One significant behavioral problem
associated with prenatal exposure to
maternal cigarette smoking (PEMCS) is
the increased rate of experimentation
with drugs of abuse in childhood, adoles-
cence, and adulthood.4 This association
might be mediated by a direct effect of
prenatal exposure to nicotine, the major
psychoactive compound in cigarettes, on
reward-related neural circuitry. Acting
on neuronal nicotinic receptors, nicotine
modulates the release of neurotransmit-
ters and neuropeptides associated with
drug reward.5 Based on a number of
experiments in animals, it has been sug-
gested that chronic exposure to nicotine
during prenatal development influences
the reward circuitry and, in turn, modi-
fies the psychoactive effects of drugs
later in life.6
High-affinity nicotinic receptors are
present in the human orbitofrontal cor-
tex (OFC) and increase in number after
smoking.7 We have recently demon-
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strated that PEMCS is associated with thinning of the
human OFC among adolescent offspring.8 It has been
hypothesized that changes in the function and/or struc-
ture of the OFC could lead to an increase in substance
use.9,10 In humans, adults with drug addiction have
OFCs of smaller volume.11 Animal experiments have
demonstrated that OFC lesions lead to alterations in
cue-mediated drug intake, stimulus-reinforcement
behavior, and impulsive behavior.10,12 Human func-
tional imaging studies suggest that the OFC is sensitive
to drug-associated stimuli rather than the drug itself.13
This is consistent with studies in nonhuman primates,
which demonstrate that neuronal activity in the OFC
increases in response to cues predicting reward
stimuli.14 Thus, it appears that the OFC is important for
the processing of cues associated with rewards and for
the control of impulsive behavior. It is, therefore, likely
that structural and/or functional properties of the OFC
predict drug experimentation. This may be particularly
true when drug-taking behavior emerges, namely, dur-
ing adolescence.
In this study, we tested this hypothesis by studying
the relationship between OFC thickness and drug ex-
perimentation in a population-based sample of adoles-
cents (12-18 years of age), half of whom had been ex-
posed to maternal cigarette smoking during gestation,
matched to nonexposed adolescents by maternal educa-
tional level.
METHODS
This work reports findings of the ongoing Saguenay Youth
Study, aimed at evaluating the effects of PEMCS on brain
development and behavior as well as cardiovascular and meta-
bolic health among adolescent offspring.15 The Research Eth-
ics Committee of the Chicoutimi Hospital approved the study
protocol.
PARTICIPANTS
Adolescents and their biological parents were recruited from a
founder population of the Saguenay–Lac-Saint-Jean region of
Quebec. Both maternal and paternal grandparents of the ado-
lescents were of French Canadian ancestry born in the region;
as such, all adolescents are of a single ethnicity, namely, whites
of French Canadian ancestry. The Saguenay Youth Study uses
a family-based design in which only children with 1 or more
siblings and both biological parents are included. This design
was used to allow for linkage-based genetic analyses rather than
to select siblings discordant for PEMCS; we found that such
discordance is low (27 of 275 sibships [9.8%] in the current
sample). The current behavioral data set included 597 adoles-
cents from 275 sibships. Demographic characteristics for
the sample are reported in eTable 1 (available at http://
www.archgenpsychiatry.com). Analysis of cortical thickness and
genotyping were performed on available data from 314 ado-
lescents in 138 sibships. Demographic characteristics for these
314 participants did not differ from those of the larger sample
size used in our behavioral data set (eTable 2).
RECRUITMENT
Adolescents were recruited as previously reported.15 Briefly, re-
cruitment begins with the research team visiting all class-
rooms in a given secondary school and presenting the study to
the students. Concurrently, a brochure, a letter from the prin-
cipal, and a consent form for a telephone interview are mailed
to parents. Subsequently, a research nurse conducts a tele-
phone interview with interested families, usually with the ado-
lescent’s biological mother, to verify eligibility. Additional in-
formation is acquired using a medical questionnaire completed
by the child’s biological parent.
The main exclusion criteria for exposed and nonexposed
adolescents are: history of meningitis, malignant tumor, or heart
disease requiring surgical treatment; severe mental illness (eg,
autism, schizophrenia) or mental retardation (IQ 70); pre-
mature birth (gestational age 35 weeks); and contraindica-
tions to magnetic resonance imaging. The following inclusion
criteria are used for exposed and nonexposed adolescents: 12
to 18 years of age; 1 or more siblings in the same age group;
and maternal and paternal grandparents of French Canadian
ancestry. Exposed adolescents must have a history of mater-
nal cigarette smoking (1 cigarette per day in the second tri-
mester of pregnancy). Nonexposed adolescents are matched to
exposed adolescents based on maternal educational level and
school attended. For mothers of nonexposed offspring, we re-
quire a negative history of cigarette smoking during preg-
nancy and during the 12-month period preceding pregnancy.
Mothers of exposed and nonexposed adolescents should have
a negative history of excessive alcohol use during pregnancy
(210 mL/wk). Cigarette smoking status before and during
pregnancy is ascertained retrospectively by a research nurse dur-
ing a structured telephone interview with the adolescent’s
mother. We assessed the overall agreement between exposure
status noted in the medical records during pregnancy and ma-
ternal report during the telephone interview using a  statistic
and found a mean (SD) value of 0.69(0.04), indicating a good
agreement.15
MAGNETIC RESONANCE IMAGING
Magnetic resonance imaging data were collected as reported
previously.15 Briefly, magnetic resonance images were
acquired on a Philips 1.0-T superconducting magnet (Gyro-
scan NT; Philips Medical Systems, Best, the Netherlands).
High-resolution anatomical T1-weighted images were
acquired using the following parameters: 3-dimensional
radio frequency–spoiled gradient echo scan with 140 to 160
sagittal slices, 1-mm isotropic resolution, a 25-millisecond
repetition time, a 5-millisecond echo time, and a 30° flip
angle. We measured cortical thickness using FreeSurfer, a
set of automated tools for reconstruction of the brain corti-
cal surface.16 For every participant, FreeSurfer segments the
cerebral cortex, the white matter, and other subcortical
structures and then computes approximately160 000 trian-
gular meshes that recover the geometric and topological
characteristics of the pial surface and the gray/white matter
interface of the left and right hemispheres. Local cortical
thickness is measured based on the difference between the
position of equivalent vertices in the pial and gray/white
matter surfaces. A correspondence between cortical surfaces
across participants is established using a nonlinear align-
ment of the principal sulci in each participant’s brain with a
reference brain.17 In FreeSurfer, what we describe in this
study as the OFC is classified by the software as the lateral
OFC, as previously defined.17 Based on the anatomical par-
cellation of the OFC by Chiavaras et al,18 we defined the
OFC as including the anterior, medial, and posterior OFC
but excluding the adjacent gyrus rectus (defined by Free-
Surfer as the medial OFC) and the lateral orbital gyrus (de-
fined by FreeSurfer as the pars orbitalis). The latter 2
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FreeSurfer-based segments extend beyond the OFC onto
other frontal areas on the medial and lateral convexity.
GENOTYPING
A single-nucleotide polymorphism in the brain-derived neu-
rotrophic factor (BDNF) gene (rs6265; G/A) with the minor A
allele was genotyped using the KASPar system (KBiosciences,
Hoddesdon, England). KASPar is a competitive allele-specific
polymerase chain reaction–based single-nucleotide polymor-
phism genotyping system that uses fluorescence resonance en-
ergy transfer quencher cassette oligonucleotides. Quality of geno-
typing was assured by validating the assay with an in-house panel
consisting of 44 samples from white participants, with all geno-
types falling within the Hardy-Weinberg equilibrium. In addi-
tion, all DNA samples were tested with 2 in-house quality-
control assays to guarantee the high quality of genomic DNA.
Finally, 2 different KBiosciences personnel independently scored
all genotypes. The rs6265 genotype distribution in the Saguenay
Youth Study cohort (Val/Val: GG, 66.1%; Val/Met: GA,28.4%;
Met/Met: AA,5.5%; n=310) was similar to that reported in other
population-based cohorts.19 Moreover, allele frequencies did not
differ between exposed and nonexposed groups. Of 314 ado-
lescents genotyped, 4 (1.3%) were excluded because of miss-
ing genotype values.
PSYCHIATRIC SYMPTOMS
AND SUBSTANCE USE
Adolescents
The likelihood of psychiatric diagnosis was assessed using
the Diagnostic Interview Schedule for Children Predictive
Scales (DPS),20 a “brief diagnostic-specific self-report inven-
tory that identifies youths endorsing symptoms and who are
highly likely to meet diagnosis criteria.”21(p833) The scale has
previously been validated against the Diagnostic Interview
Schedule for Children 20 and Voice–Diagnostic Interview
Schedule for Children.21
In the DPS, 15 questions concern the use of and problems
associated with alcohol (4 questions), marijuana (3 ques-
tions), and other substances (8 questions). We combined the
3 types of substances into a single cluster, named substance use,
as in previous studies.20,21 The sum of all positive answers (maxi-
mum score, 15) was used as the main outcome variable in the
analysis of the effect of PEMCS on substance use. For the total
sample (n=597), scores on the 15-item DPS scale ranged from
0 to 13 (mean [SD], 1.16 [1.84]). For the MRI sample (n=314),
DPS scores ranged from 0 to 13 (mean [SD], 1.25 [1.89]). In
addition to the substance use score, we also calculated a com-
posite measure of all current adolescent psychiatric symp-
toms, excluding substance use.
To provide an index of drug exposure complementary to
DPS, we also collected information about adolescent drug ex-
perimentation by asking 15 questions about the use of alco-
hol, cigarettes, marijuana, and other illicit drugs, namely, stimu-
lants, psychedelics, PCP, Ecstasy, prescription drugs, inhalers,
cocaine, opiates, tranquilizers, heroin, anabolic steroids, and
other drugs not listed (eAppendix); these questions had been
used previously22 and, for this study, were incorporated in the
GRIPado (Groupe de recherche sur l’inadaptation psychoso-
ciale chez l’enfant [Research Unit on Children’s Psychosocial
Maladjustment] adolescent) questionnaire. The outcome mea-
sure was the sum of positive answers to the 15 questions re-
garding lifetime history of drug use. Mean (SD) scores on the
15-item GRIPado scale were 1.56 (1.87) (range, 0-11) for the
total sample (n=597) and 1.70 (1.87) (range, 0-11) for the MRI
sample (n=314). There was a strong correlation between the
DPS and GRIPado scales (total sample: r2=0.63, P .001; and
MRI sample: r2=0.57, P .001).
We also assessed drug use by peers, as reported by the
target adolescent, which was included in the Positive Youth
Development questionnaire,23 a composite measure of
friends who smoked, drank, or did drugs. Finally, current
parental monitoring and level of warmth were assessed by
the adolescent and included in the Positive Youth Develop-
ment questionnaire.
Parents
We assessed frequency of current symptoms of depression
and anxiety of the biological father and mother.24 Parental
assessments of cigarette, alcohol, and drug use were based
on the National Survey on the Health of the Population and
developed by the project team of the Saguenay Youth
Study.15 Finally, the assessment of parental antisocial behav-
ior during adolescence and adulthood was based on that of
Zoccolillo et al.22
OTHER VARIABLES
Adolescents’ general intelligence was assessed with the Wechs-
ler Intelligence Scale for Children. Self-attributes were also as-
sessed through the questionnaire on resistance to peer influ-
ence.25 Data on pregnancy, birth, and the early postnatal period
were obtained through a structured interview with the biologi-
cal mother and a medical questionnaire administered to a bio-
logical parent; duration of pregnancy, use of alcohol and drugs
during pregnancy, birth weight, and breastfeeding data were
acquired as previously described.15 Socioeconomic variables in-
cluded parental educational levels and household income as
well as several additional measures such as perception of fi-
nancial difficulties.15
STATISTICAL ANALYSIS
Behavioral Data
Statistical analysis of behavioral data was performed using hier-
archical linear modeling (HLM statistical software, version 6.0;
Scientific Software International, Lincolnwood, Illinois). Using
HLM, we could account for the clustering of sibling pairs within
families. This procedure allowed us to determine the relation-
ship of the offspring and family predictors with the main out-
come variable, namely, the total score on the DPS-based substance-
use cluster. This technique ensures that the appropriate estimates
of standard errors are calculated.26 Within HLM, parental data are
specified as a level 2 variable, which estimates between-family ef-
fects, and the sibling data as a level 1 variable, which models within-
family variability. This structure allows one to model how family-
level variables influence sibling-level variables and to calculate
the correct error terms, as well as to take into account the inter-
dependence within a family and examine the influence of the
single-parent estimates of socioeconomic status or antisocial be-
havior on each of the sibling scores without double or triple count-
ing, leading to pseudoreplication, as would be the case in stan-
dard regression.
Because the distribution of the outcome variable was highly
skewed, we transformed the data using Poisson distribution.26
We then identified possible offspring-based confounders of
PEMCS, such as breastfeeding, or parent-based predictors of
substance use, such as parental antisocial behavior, and in-
cluded these in the multivariate analyses carried out with HLM.
To ensure numerical stability for HLM analysis and its inter-
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pretation, each of the offspring and parental predictor vari-
ables was evaluated for collinearity and for the selection of the
correct location of their respective intercepts.26
We built our predictor models using theoretical and em-
pirical considerations, as addressed in the book by Rauden-
bush and Bryk.26 We used a “step-up” strategy of building up
from a univariate to a multivariate model. To determine which
predictors should remain in the model and which should be
omitted, we added variables individually and tested the linear-
ity of the predictor variable with that of the outcome vari-
able.26 Only the predictor variables that illustrated signifi-
cance (P .05) of the associated coefficients were retained in
the final model. Once the offspring-based model was deter-
mined, we added parental variables to the model. The ap-
proach to model building for parental predictors was similar
to that described for the offspring predictors. We divided con-
ceptually our parental predictors into “distinct subsets and fit-
ted the submodel for each.”26(p267) At the end of our analysis,
no parental predictors remained significant. Moreover, be-
cause data were missing for some variables, a small number of
participants, with equal distribution in the exposed and non-
exposed groups, were excluded from the final analysis (Table).
The final formula for the remaining significant offspring pre-
dictors is shown below:
Log[Sum of Scores on Full-Scale DPS Substance Use
Disorder Questions]=B0  B1  (Exposure) 
B2  (Friends Smoking, Drinking, and Doing Drugs)
 B3  (Age in Months)  B4  (Full DPS-Rated
Psychiatric Symptoms),
in which B0 is the intercept of the equation, and B1 through
B4 represent the slope of the indicator variables. Predictors in
boldface type represent group-mean centered variables.
CORTICAL THICKNESS
Analysis of cortical thickness was performed using data from
314 adolescents. Data evaluating the associations between geno-
type, behavior, and cortical thickness used a linear model that
included the main effects as well as their interactions (JMP sta-
tistical software, version 5.1.2, SAS Institute Inc, Cary, North
Carolina). Given the known age and sex effects on cortical thick-
ness,8 and those observed in our current sample, we used age-
and sex-corrected OFC thickness values in our analyses. Of 314
participants in the initial sample, 8 (2.5%) were excluded be-
cause of missing values relating to drug use, 4 (1.3%) for miss-
ing genotype data, and 1 (0.3%) for missing both drug intake
and genotyping data (final sample size, n=303).
RESULTS
ADOLESCENT SUBSTANCE USE
Our findings revealed that PEMCS is associated with a
1.5-fold increase in substance use(P=.01) (Table). Other
factors predicting substance use included adolescent’s age,
peer drug use, and adolescent psychiatric symptoms
(P .001) (Table). Sex and sex exposure were not sig-
nificant predictors of DPS substance use scores. These
findings illustrate that PEMCS is associated with an in-
crease in substance use among adolescents, even after con-
trolling for other variables such as age and peer drug use.
Inclusion of potential confounders, such as birth weight,
breastfeeding, mother’s alcohol use during pregnancy, and
parental history of antisocial behavior during adoles-
cence and adulthood, did not alter these results.
CORTICAL THICKNESS AND DRUG USE
Several lines of evidence point to the possible involve-
ment of the OFC in influencing substance use behavior.
Therefore, we tested the hypothesis that the thickness
of the OFC is associated with the number of different drugs
tried by adolescents in their lifetime, as assessed by the
GRIPado. Cortical thickness was evaluated in a subset
of 314 participants for whom measures of cortical thick-
ness were available at the time of analysis. This group
had demographic characteristics nearly identical to the
larger behavioral sample (eTables 1 and 2). We ob-
served a main effect for PEMCS (F3,302=11.3; P .001),
as reported previously,8 but no main effect for the num-
ber of drugs tried (F3,302=0.09; P=.76). More important,
we observed a 2-way interaction between the effect of
PEMCS and the number of drugs tried by the adolescent
on OFC thickness (F3,302=18.6; P .001). As predicted,
among 150 exposed adolescents, more drug experimen-
tation was associated with a thinner OFC (R2=0.08;
P .001) (Figure). Among 156 nonexposed adoles-
cents, however, trying more types of drugs was associ-
ated with a thicker OFC (R2=0.05; P=.007) (Figure). We
propose that the association between OFC thickness and
drug experimentation among nonexposed adolescents rep-
Table. Predictors of Substance Use
Variable Name
Standardized
Coefficienta T Ratio P Value
Total Sample (n=597; df=457)
Prenatal exposure to maternal cigarette smoking 0.10 2.592 .01
Age, mo 0.21 4.366 .001
Friends smoke, drink, and do drugs 0.43 4.147 .001
Adolescent psychiatric symptoms 0.20 3.291 .001
Genotyping Sample (n=314; df=269)
Prenatal exposure to maternal cigarette smoking 0.12 2.820 .006
Age, mo 0.13 2.504 .01
Friends smoke, drink, and do drugs 0.39 3.002 .003
Adolescent psychiatric symptoms 0.22 3.393 .001
aThe formulas for calculating the standardized coefficients can be found in Hox.27
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resents a form of experience-induced plasticity. This pos-
sibility was explored next using the Val66Met func-
tional polymorphism in the BDNF gene, which is known
to influence activity-dependent release of BDNF and, in
turn, brain structure.
We found a significant 3-way interaction among BDNF
genotype, PEMCS, and the number of drugs tried in pre-
dicting OFC thickness (F7,302=5.68; P=.02); there was no
main effect of BDNF genotype (F7,302=0.03; P= .86).
Among nonexposed adolescents, the BDNF genotype in-
teracted with the number of drugs tried (F3,151=5.76;
P=.02) (Figure); this was not the case among exposed
adolescents (F3,146=0.65; P=.42). As predicted, among
nonexposed adolescents only, those with the Val/Val geno-
type (n=101) demonstrated a significant positive corre-
lation between OFC thickness and the number of drugs
tried (R2=0.13; P .001) (Figure). Among Met carriers
(ie, 54 individuals with the less efficient BDNF geno-
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Figure. The orbitofrontal cortex (OFC) in the human brain (shaded area) (A). Group differences in the relationship between the thickness of the OFC and drug
experimentation. B, Adolescents exposed or not exposed to maternal cigarette smoking during pregnancy exhibit a correlation between the number of different
drugs tried in their lifetime and the cortical thickness of the OFC. Among exposed adolescents, the degree of OFC thinning is associated with an increase in the
number of drugs tried. Among nonexposed adolescents, the increase in the number of drugs tried is associated with thickening of the OFC. Note that removing the
single outlier in the exposed and nonexposed groups, respectively, did not change the fit substantially (exposed, r 2=0.10; nonexposed, r 2=0.05). C, Orbitofrontal
cortex thickness and BDNF genotype. The thickening of the OFC as a function of the number of drugs tried was only present in nonexposed adolescents with the
efficient Val/Val BDNF genotype (left) and not the Met-carrier genotype (right). Among adolescents exposed to maternal cigarette smoking, the negative correlation
between OFC thinning and number of drugs tried did not significantly differ depending on the individual BDNF genotype (F3,146=0.65; P=.42). Note that removing
the single outlier in the Val/Val group did not change the fit substantially (r 2=0.15).
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type) no such correlation was observed (R2=0.01; P=.61).
These findings provide support for the hypothesis that,
among adolescents not exposed to maternal smoking dur-
ing pregnancy, OFC thickness is being modified by ac-
tivity-dependent release of BDNF presumably associ-
ated with drug-related behavior.
COMMENT
Our current findings demonstrate that PEMCS is asso-
ciated with a greater likelihood of drug experimenta-
tion during adolescence; the thinner the OFC, the more
different drugs had been tried by exposed adolescents;
and the more drugs tried by nonexposed adolescents, the
thicker the OFC—an effect moderated by the BDNF geno-
type. We speculate that PEMCS interferes with the de-
velopment of the OFC and, in turn, increases the likeli-
hood of drug use among adolescents. We further suggest
that, among nonexposed adolescents, drug experimen-
tation influences OFC thickness via processes akin to ex-
perience-induced plasticity.
INFLUENCES OF PEMCS
ON BRAIN STRUCTURE
In humans, several recent studies have reported an as-
sociation between PEMCS and brain structure later in life.
We have shown that PEMCS is associated with less thick-
ness of the cerebral cortex in adolescents.8 Others have
found associations between PEMCS and regional vol-
umes of cortical gray matter during early adolescence,28
as well as between PEMCS and white-matter integrity in
young adulthood.29 Together, these findings suggest sig-
nificant consequences of PEMCS on the offspring brain.
But, in the absence of longitudinal data from birth on-
ward, and owing to the difficulty of ruling out all pos-
sible confounders of cigarette smoking during preg-
nancy in human studies, the directionality and causality
of these effects can be established only in experimental
studies in animal models. In such studies, pregnant dams
are exposed to nicotine, the primary constituent in to-
bacco smoke. Roy and Sabherwal30 illustrated that long-
term exposure to gestational nicotine decreased the thick-
ness of the somatosensory cortex among offspring at all
ages examined, namely, at postnatal days 10, 20, and 40,
which corresponds to adolescence. Further histological
analysis suggested that the nicotine-induced reduction
in cortical thickness was related to reductions in den-
dritic complexity and soma size but not to a loss of cells.30
Later studies suggest that prenatal exposure to nicotine
induces cytoplasmic vacuolation, enlargement of inter-
cellular spaces, and an increase in the number of apop-
totic cells.31 Primate studies have provided supportive evi-
dence by illustrating that tobacco exposure during
pregnancy can lead to decreases in cell size, increases in
cell-packing density, and a reduction in cell number, es-
pecially in the temporal cortex.32 Although these stud-
ies have evaluated the effects of nicotine, it is important
to acknowledge the potential role of other major con-
stituents in tobacco smoke, some of which have been
shown to interact with nicotine.33,34
Altogether, we suggest that the effect of maternal smok-
ing during pregnancy on the developing brain and, in par-
ticular, the OFC, influences the likelihood of experi-
menting with drugs during adolescence. For a large
number of exposed adolescents who have not experi-
mented with any substances, OFC thickness is compa-
rable to that of nonexposed adolescents with the same
drug-free history (Figure). These findings further sup-
port the hypothesis that only exposed individuals with
a thinner OFC are more susceptible to increased drug ex-
perimentation.
DRUG-TAKING BEHAVIOR
AND OFC DYSFUNCTION
The most extensive effects of PEMCS on cortical thin-
ning were observed in the OFC, as reported previously.8
It is possible that PEMCS interferes with OFC develop-
ment, leading to functional consequences, namely,
higher probability of drug experimentation. The OFC
has been directly linked to impulsivity and cue-
associated reward processing in nonhuman primates.12
In rats, prenatal exposure to nicotine increases the dose
of cocaine necessary to maintain its self-administration,
thus suggesting an increased reward threshold.6 In
humans, several imaging studies of adults with drug
addiction identified changes in cerebral blood flow and
glucose metabolism in the OFC.9,13,35 Higher cerebral
blood flow in the OFC during the performance of the
Iowa Gambling Task was observed in participants
addicted to cocaine compared with control participants,
suggesting greater OFC engagement in the anticipation
of reward among these individuals.9 During protracted
withdrawal, however, adults with drug addiction exhibit
lower glucose metabolism in the OFC than do controls,
as measured by positron emission tomography.35 This
finding is consistent with the results of structural mag-
netic resonance imaging studies that have found lower
volumes of gray matter in the OFC and prefrontal corti-
ces in adults with drug addiction, compared with con-
trols.11,36 Our finding of a negative relationship between
OFC thickness and drug experimentation could be
related to either higher impulsivity or higher reward
threshold among exposed adolescents with progressively
lower OFC thickness.
EXPERIENCE-INDUCED PLASTICITY
We found that increasing OFC thickness correlates with
the number of drugs tried only among nonexposed ado-
lescents with the Val/Val genotype, which is known for
its more efficient activity-dependent release of BDNF; this
was not the case among adolescents with the Met/Val or
Met/Met genotypes. This suggests that cortical thick-
ness among nonexposed adolescents reflects a gene
(BDNF) and environment (drug use) interaction. The pri-
mary substance use variable in our analyses was the num-
ber of different drugs tried by adolescents during their
lifetime. It is likely that this is a good predictor of the
overall likelihood of drug-taking behavior, as shown by
the positive correlation between the number of differ-
ent drugs tried in the lifetime and the number of days of
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marijuana smoking in the last 30 days; marijuana was
the most commonly used illicit drug in our population
(total sample: R2=0.33; F1,86=42.3; P .001; and MRI
sample: R2=0.24; F1,59=18.5; P .001).
Drugs of abuse are known to have a significant effect
on the structure and function of the brain.37 Although
the mechanisms remain unknown, a number of molecu-
lar pathways have been proposed.37 Neurotrophic fac-
tors represent one such candidate system37,38 known to
influence dendritic complexity, as well as cell size and
survival, axonal outgrowth, and synaptic plasticity.
Through a series of recent experiments, drug-induced
changes in BDNF release and its consequences on struc-
tural plasticity have been demonstrated.39 BDNF expres-
sion in the frontal cortex, compared with other brain re-
gions, appears to be particularly susceptible to drug
use.40 Moreover, the effects appear to be drug specific.
Although exposure to stimulants has been shown to
increase dendritic complexity and the number of den-
dritic spines in the prefrontal cortex, opiate exposure
appears to exert the opposite effect.37 In our popula-
tion, the illegal substances most commonly used by
adolescents were marijuana, stimulants, and psyche-
delic drugs.
Mice with forebrain-restricted knockout of BDNF ex-
hibit cortical thinning of the somatosensory and visual
cortices; this effect is attributed to a decrease in den-
dritic arborization and cell size but not necessarily to a
loss in cell number.41 In humans, the Val to Met substi-
tution has been shown to alter the prodomain of the BDNF
protein, which inhibits its packaging into secretory gran-
ules.42 This change ultimately decreases activity-
dependent release of BDNF in Met carriers.42 Structural
differences in the brain of healthy individuals with the
different Val/66/Met BDNF genotype include alter-
ations in the volume of gray matter in the hippocampus,
amygdala, and thickness of the prefrontal cortex.43,44
We conclude that the effect of an adolescent’s drug-
taking experience on brain structure could be modified
by genetic makeup, with BDNF as a critical player. Fu-
ture longitudinal studies evaluating the structure of the
brain before, during, and after the onset of drug use are
necessary to explore these findings further. This gene-
environment interaction was present, however, only in
adolescents not exposed to maternal cigarette smoking
in utero. This raises an important methodological con-
sideration for future studies and an interesting scientific
question: Is it possible that PEMCS renders BDNF less
effective regardless of the genotype?
A COMMON LINK
In experimental animals, the effect of prenatal exposure
to nicotine and the BDNF knockout are remarkably simi-
lar: both decrease cortical thickness and reduce den-
dritic branching. In humans, serum BDNF levels are di-
minished in long-term smokers but return to normal levels
following cessation of cigarette smoking, thus suggest-
ing a negative effect of cigarette smoke on BDNF expres-
sion.45 Kenny et al5 found that short- and long-term nico-
tine exposure can influence BDNF expression (messenger
RNA) in the brain of the adult rat. Maternal smoking dur-
ing pregnancy is associated with a higher rate of DNA
methylation among offspring.46 We speculate that PEMCS
is associated with an epigenetic modification of the BDNF
gene that, in turn, decreases the likelihood of its expres-
sion in response to neural activity. Such a modification
may represent a mechanism for PEMCS-induced inter-
ference with cortical development and explain the lack
of moderating effect of the BDNF genotype on the rela-
tionship between OFC thickness and the number of dif-
ferent drugs tried by exposed adolescents. We cannot rule
out the possibility that the lack of differences in the re-
lationship between OFC thickness and the number of
drugs tried is owing to other biological or methodologi-
cal issues. But, the similarity of the exposed and nonex-
posed groups in the number of Val/Val homozygotes and
Met carriers and in age and sex, as well as the fact that
they all come from the same white founder population,
argues against the latter.
STRENGTHS AND LIMITATIONS
The main strengths of the Saguenay Youth Study cohort
include the matching of nonexposed with exposed ado-
lescents by maternal educational level, a detailed assess-
ment of adolescents’ family environment and cognitive
abilities, as well as the relatively high cultural and ge-
netic homogeneity of the region.15 One of the main limi-
tations of the study is the fact that PEMCS was deter-
mined by maternal reports, which may be subject to recall
bias. As described elsewhere,15 however, we verified most
maternal reports using medical records completed dur-
ing pregnancy. Furthermore, the observed differences in
birth weight for exposed vs nonexposed adolescents15 also
support the validity of the retrospective assessment of ma-
ternal smoking during pregnancy in our sample. Fi-
nally, it has been suggested that underreporting of smok-
ing may be higher at the time of pregnancy because of
the immediate influence of the stigma associated with
smoking while pregnant.47
CONCLUSION
First, we report that PEMCS is associated with higher
substance use during adolescence. Second, we demon-
strate a moderating effect of PEMCS on the relationship
between the thickness of the OFC and drug experimen-
tation. Finally, we document a moderating effect of
BDNF genotype on the same structure-function rela-
tionship in adolescents not exposed to prenatal mater-
nal cigarette smoking. We propose 2 separate mecha-
nisms that may mediate drug-taking behavior in our
adolescent population. First, given the existing litera-
ture on animal models, we speculate that PEMCS
induces changes in OFC thickness and, in turn, influ-
ences the likelihood of drug experimentation during
adolescence. Second, in the nonexposed population, we
suggest that age acts as a significant predictor of sub-
stance use, through maturational changes in sensitivity
to drug reward or through enhanced access to drugs
during adolescence. Finally, among nonexposed adoles-
cents, we propose that BDNF genotype modulates
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experience-driven plasticity related to drug use, which
then affects OFC thickness. Longitudinal studies in
humans and experimental animals are needed to pro-
vide further evidence to support these findings.
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